INSIGHTEC, founded in 1999, develops and distributes the Exablate platform which provides non-invasive treatments for a variety of neurosurgery, oncology and gynecology indications. The Exablate platform uses revolutionary MRgFUS technology which combines high intensity focused ultrasound guided by Magnetic Resonance Imaging (MRI). Focused ultrasound waves, guided by magnetic resonance imaging are used to safely ablate targeted tissue, ensuring a high rate of effectiveness with minimal side effects. INSIGHTEC is continuously investing and expanding its current and investigational applications, ranging from functional neurosurgery to oncology and gynecology. With over 14,000 Exablate treatments to date, MRgFUS technology is embraced by world renowned physicians in more than 120 medical facilities. The company has received numerous innovation awards – among them are The Prix Galien, The Wall Street Journal and TIME magazine. INSIGHTEC is privately held by GE Healthcare, Elbit Imaging, York Capital Management, GEOC Hengtong Investment Limited Partnership and MediTech Advisors.
Category: Medical Device
Sub-category: Medical Equipment, Minimally Invasive Treatment
Therapeutic Area(s): Neuroscience, Urology, Oncology, Women’s’ Health, Gynecology.
Company Status: Initial Revenues
To learn more about the company please visit their website: www.insightec.com
The company’s officials visited New Delhi and Jaipur end of July as part of the Medical Delegation coming from Israel to India.
In order to meet them or know more about the activity please contact:
Mr. Tejinder Singh, Senior Trade Officer, New Delhi – firstname.lastname@example.org